Oberg Johanna, Verelst Margareta, Jorde Rolf, Cashman Kevin, Grimnes Guri
Tromsø Endocrine Research Group, Institute of Clinical Medicine, UiT-The Arctic University of Norway, Tromsø, Norway.
Department of Obstetrics and Gynecology, University Hospital of North Norway, Tromsø, Norway.
J Steroid Biochem Mol Biol. 2017 Oct;173:28-32. doi: 10.1016/j.jsbmb.2017.03.013. Epub 2017 Mar 18.
Lower urinary tract symptoms (LUTS) are common in postmenopausal women, and have been reported inversely associated with vitamin D intake and serum 25-hydroxyvitamin D (25(OH)D) levels. The aim of this study was to investigate if high dose vitamin D supplementation would affect LUTS in comparison to standard dose. In a randomized controlled study including 297 postmenopausal women with low bone mineral density, the participants were allocated to receive capsules of 20 000IU of vitamin D twice a week (high dose group) or similar looking placebo (standard dose group). In addition, all the participants received 1g of calcium and 800IU of vitamin D daily. A validated questionnaire regarding LUTS was filled in at baseline and after 12 months. At baseline, 76 women in the high dose group and 82 in the standard dose group reported any LUTS. Levels of serum 25(OH)D increased significantly more in the high dose group (from 64.7 to 164.1nmol/l compared to from 64.1 to 81.8nmol/l, p<0.01). No differences between the groups were seen regarding change in LUTS except for a statistically significant reduction in the reported severity of urine incontinence in the high dose group as compared to the standard dose group after one year (p<0.05). The results need confirmation in a study specifically designed for this purpose.
下尿路症状(LUTS)在绝经后女性中很常见,并且有报道称其与维生素D摄入量及血清25-羟基维生素D(25(OH)D)水平呈负相关。本研究的目的是调查与标准剂量相比,高剂量补充维生素D是否会影响下尿路症状。在一项纳入297名低骨密度绝经后女性的随机对照研究中,参与者被分配接受每周两次20000IU维生素D胶囊(高剂量组)或外观相似的安慰剂(标准剂量组)。此外,所有参与者每天接受1g钙和800IU维生素D。在基线时和12个月后填写一份关于下尿路症状的有效问卷。基线时,高剂量组有76名女性、标准剂量组有82名女性报告有任何下尿路症状。高剂量组血清25(OH)D水平升高更为显著(从64.7nmol/l升至164.1nmol/l相比,标准剂量组从64.1nmol/l升至81.8nmol/l,p<0.01)。除了一年后高剂量组报告的尿失禁严重程度相比标准剂量组有统计学显著降低(p<0.05)外,两组在下尿路症状变化方面未见差异。该结果需要在专门为此目的设计的研究中得到证实。